AstraZeneca: heart drug studies yield positive findings

(CercleFinance.com) - AstraZeneca has unveiled the results of a trial that provides information about the longer-term management of patients who had undergone coronary intervention.


It appeared in particular that treatment with its Brilinta monotherapy, without aspirin, reduced the risk of bleeding compared to Brilinta plus aspirin over 12 months in this subgroup of high-risk patients.

These findings - which seem to challenge the conventional paradigm for maintenance of aspirin in coronary syndrome patients - were presented at the American Heart Association (AHA) congress in Philadelphia yesterday.

AstraZeneca also announced new data from five additional analyses of a landmark Phase III trial, showing that its Farxiga drug reduced the risk of worsening heart failure or death from cardiovascular causes versus placebo, when added to standard of care.

The AstraZeneca share is up 0.3% in London this morning.

Copyright (c) 2019 CercleFinance.com. All rights reserved.